TCRX (tscan.com) Earnings per share growth rate in current year
TScan Therapeutics (TCRX) demonstrates high macro resilience, as the success of cell therapy depends on medicine rather than GDP. On the GURU.Markets platform, the year-over-year EPS growth trend clearly illustrates a recovery in margins, where 20.30 determines the current status of the parameter. Growth potential is driven by massive demand for solid tumor treatments and the implementation of sustainable, zero-waste laboratory technologies.
Financial and market metric breakdowns for tscan.com (TCRX)
- stock price and consensus target price:
- business market valuation indicators:
- balance sheet equity data:
- debt and solvency information:
Total Debt to Equity Ratio TScan Therapeutics|TCRX - Long-Term Debt to Capital|Short-Term Debt to Capital TScan Therapeutics, Inc.|TCRX - Company Debts|Debt to Book Value Ratio TCRX|TCRX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings TScan Therapeutics|Intermediate Liquidity Ratio tscan.com
- earnings and valuation multiples indicators:
TCRX - Net Profit|Expected Net Income TScan Therapeutics|TCRX - P/E Multiple|Projected Price to Earnings Ratio TScan Therapeutics, Inc.|TCRX - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation TCRX|TCRX - Operating profit EBITDA|Net earnings per share (EPS TTM) TScan Therapeutics|TCRX - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months tscan.com|TCRX - Earnings growth in current year|Expected net earnings per share growth next year TScan Therapeutics
Basic company analysis:TScan
TScan Therapeutics' unique T-cell therapy platform lays the foundation for long-term capitalization through personalized oncology. This indicator measures the annual dynamics of net earnings per share, allowing for an assessment of business scaling efficiency. The metric filters out short-term market noise to reveal the actual profitability trend. It is critical for investors to correlate this data with asset liquidity. By analyzing the year-over-year volatility of earnings per share, one can determine the sustainability of financial growth.
Key competitors
BeiGene Ltd. - Earnings per share increase in current year|HALO (Halozyme Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Revolution Medicines Corp RVMD|Net earnings per share growth this year AAPG (Ascentage Pharma Group)|Net earnings per one share growth for the current year CGON|Earnings per share growth in current year UroGen Pharma URGN|Expected net earnings per share growth this year Bicara Therapeutics Inc (BCAX)|Personalis Corp - Earnings growth in current year|Erasca Oncology (ERAS) - Net earnings per share growth this year|DCTH: Earnings growth in current year|ymabs.com (YMAB) - Earnings growth in current year|Earnings per share growth in current year Aura Biosciences|Earnings per share growth this year CADL (Candel)|Net earnings per share growth this year ARAY (Accuray Inc.)|SLS (sellaslifesciences.com) - Earnings per share increase in current year|Actuate Therapeutics, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year CTOR (citiusonc.com)|TuHURA - Earnings growth in current year|Earnings per share increase in current year TARA (Protara Therapeutics Inc)|FATE: Earnings growth in current year|Earnings per share growth rate in current year Aadi Bioscience (WHWK)|Earnings per share growth in current year Champions Oncology Inc|XBIT: Earnings per share increase in current year|Earnings growth in current year CVM|Earnings growth in current year OS Therapies Inc. (OSTX)|Earnings per share growth in current year Radiopharm Theranostics RADX|ARTV (Artiva Biotherapeutics Inc.) - Earnings per share trend in current year|Adlai Nortye Limited - Earnings growth in current year|Earnings per share growth rate in current year verupharma.com|TPST (Tempest Therapeutics, Inc.) - Net earnings per share growth this year|Xilio Therapeutics (XLO) - Earnings growth in current year|Net earnings per share growth this year RENB|MURA (Mural Bio) - Net earnings per one share growth for the current year|Earnings growth in current year KAPA|Expected net earnings per share growth this year onkuretherapeutics.com|Earnings growth in current year GDTC (CytoMed Therapeutics Limited)|CRIS - Net earnings per share growth this year|APLM - Earnings per share growth in current year|Expected net earnings per share growth this year Tharimmune Corporation THAR|ADVB (advanbiomed.com) - Net earnings per share growth this year|GNPX: Net earnings per one share growth for the current year|CLDI (Calidi Biotherapeutics Inc.) - Earnings growth in current year|Net earnings per share growth this year sunshinebiopharma.com (SBFM)|Earnings per share growth in current year Xenetic Biosciences (XBIO)|SLRX (Salarius Pharma) - Earnings per share increase in current year|Purple Biotech - Net earnings per share growth this year|AONC: Earnings per share growth this year|BeiGene - Earnings growth in current year|Checkpoint Therapeutics Inc. (CKPT) - Net earnings per share growth this year|ELEV: Earnings growth in current year|iCAD (ICAD) - Earnings growth in current year|Earnings per share growth in current year Ikena Oncology Inc.|Earnings per share growth this year NTBL (notablelabs.com)|Earnings growth in current year VIRX|Net earnings per share growth this year MorphoSys Inc MOR|Earnings growth in current year NAYA (NAYA Bio)|Ascentage (AAPGV) - Earnings per share growth rate in current year
